Biomarkers in bronchopulmonary cancer (Q37692666)

22 August 2017

1 reference

title

Biomarkers in bronchopulmonary cancer (English)

1 reference

22 August 2017

0 references

María Martín Ureste

1

1 reference

22 August 2017

Regina Gironés Sarrió

series ordinal

2

1 reference

22 August 2017

Joaquín Montalar Salcedo

series ordinal

3

1 reference

22 August 2017

publication date

1 February 2010

1 reference

Clinical and Translational Oncology

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

92-99

1 reference

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0475-Y

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0475-Y

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

12 December 2020

Three distinct regions involved in 3p deletion in human lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

12 December 2020

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

12 December 2020

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

1 reference

12 December 2020

Molecular abnormalities in lung cancer

1 reference

12 December 2020

1 reference

12 December 2020

Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma

1 reference

12 December 2020

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

12 December 2020

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

12 December 2020

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

1 reference

12 December 2020

Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer

1 reference

12 December 2020

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

12 December 2020

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

12 December 2020

Molecular analysis-based treatment strategies for the management of non-small cell lung cancer

1 reference

12 December 2020

Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression

1 reference

12 December 2020

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

1 reference

12 December 2020

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

12 December 2020

[Prognostic and predictive factors in lung cancer].

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

The FHIT gene 3p14.2 is abnormal in lung cancer.

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis

1 reference

12 December 2020

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

1 reference

12 December 2020

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

12 December 2020

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

The biology of non-small-cell lung cancer: identifying new targets for rational therapy

1 reference

12 December 2020

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

12 December 2020

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Lung cancer biology: a genetic and genomic perspective.

1 reference

12 December 2020

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

1 reference

12 December 2020

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

1 reference

12 December 2020

The cancer biomarker problem

1 reference

12 December 2020

Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer

1 reference

12 December 2020

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

1 reference

12 December 2020

Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival

1 reference

12 December 2020

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development

1 reference

12 December 2020

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

1 reference

12 December 2020

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

1 reference

12 December 2020

A five-gene signature and clinical outcome in non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S12094-010-0475-Y

Identifiers

DOI

1 reference

release_mdny5gehnzd5jl7wieobgeqgbu

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mdny5gehnzd5jl7wieobgeqgbu

24 November 2022

mapped directly with Wikidata item

1 reference